Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for PTN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 -4.417M
December 31, 2025 -4.807M
September 30, 2025 -1.619M
June 30, 2025 -4.089M
March 31, 2025 -5.354M
December 31, 2024 -4.847M
September 30, 2024 -7.016M
June 30, 2024 -6.472M
March 31, 2024 -8.607M
December 31, 2023 -10.48M
September 30, 2023 -5.906M
June 30, 2023 -9.606M
March 31, 2023 -1.408M
December 31, 2022 -9.676M
September 30, 2022 -8.581M
June 30, 2022 -7.719M
March 31, 2022 -9.492M
December 31, 2021 -6.289M
September 30, 2021 -6.424M
June 30, 2021 -8.536M
March 31, 2021 -3.504M
December 31, 2020 -14.42M
September 30, 2020 3.813M
June 30, 2020 -6.076M
March 31, 2020 -2.512M
Date Value
December 31, 2019 -4.922M
September 30, 2019 54.84M
June 30, 2019 -6.945M
March 31, 2019 -3.808M
December 31, 2018 -5.491M
September 30, 2018 -5.538M
June 30, 2018 10.49M
March 31, 2018 -7.232M
December 31, 2017 -2.993M
September 30, 2017 1.435M
June 30, 2017 -12.89M
March 31, 2017 43.50M
December 31, 2016 -11.13M
September 30, 2016 -6.599M
June 30, 2016 -13.70M
March 31, 2016 -10.22M
December 31, 2015 -14.05M
September 30, 2015 -9.398M
June 30, 2015 -9.471M
March 31, 2015 -5.309M
December 31, 2014 -4.303M
September 30, 2014 5.725M
June 30, 2014 -4.520M
March 31, 2014 -1.495M
December 31, 2013 -4.147M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Decoy Therapeutics, Inc. -2.652M
ACADIA Pharmaceuticals, Inc. 100.78M
Alnylam Pharmaceuticals, Inc. 326.72M
Anika Therapeutics, Inc. -0.684M
Savara, Inc. -29.75M